Provectus Pharmaceuticals (OTCBB: PVCT) is a development-stage oncology and dermatology biopharmaceutical company. PV-10, the company’s novel oncology drug, is designed to selectively target and destroy cancer cells without harming the surrounding healthy tissue. Provectus has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Phase 2 trials were also recently completed for the drug as a therapy for metastatic melanoma. For more information, visit the company’s Web site at www.pvct.com

B. Riley & Co. provides a full array of corporate finance, research, sales, trading, and otcqx dad services to corporate, institutional, and high net worth clients.  Headquartered in Los Angeles, with offices in San Francisco, New York, and Newport Beach, the firm is recognized for its distinguished equity research, merger and acquisitions advisory services, initial and secondary public offerings, and institutional private placements. For more information on B. Riley & Co., visit www.brileyco.com

Let us hear your thoughts below: